Nymox Pharmaceutical Corp. has announced that its long-term extension prospective double-blind Phase 3 clinical trials  of fexapotide triflutate (NX-1207) as a single-injection treatment in benign prostatic hyperplasia (BPH) patients have met their primary ... Read more